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Abstract 135 
Objectives: A prospective international multicentre 136 
surveillance study was conducted to investigate the 137 
prevalence and amphotericin B (AMB) susceptibility of 138 
Aspergillus terreus species complex infections. 139 
Methods: Three hundred seventy cases from 21 countries 140 
were evaluated. 141 
Results: The overall prevalence of A. terreus species complex 142 
among patients investigated and with mold positive cultures 143 
was 5.2% (370/7116). AMB MICs were ranging from 0.125 to 144 
32 mg/L, (median 8mg/L).  145 
Conclusions: A. terreus species complex infections cause a 146 
wide spectrum of aspergillosis and the majority of cryptic 147 
species display high AMB MICs.   148 
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Introduction: 149 
Aspergillus terreus species complex holds an exceptional 150 
position within the aspergilli, as it appears to be a rare 151 
pathogen of infection and displays polyene resistance [1,2,3]. 152 
A. terreus is a common cause of invasive aspergillosis (IA) at 153 
the M. D. Anderson
 
Cancer Center in Houston, USA, and the 154 
University
 
Hospital of Innsbruck, Austria [3,4,5]. Almost no 155 
data are available on how frequently this species occurs 156 
elsewhere and whether differences within amphotericin B 157 
(AMB) susceptibility exist. Our objective was to investigate the 158 
global prevalence of A. terreus species complex in fungal 159 
diseases and to survey AMB susceptibility. 160 
 161 
Methods: 162 
An international surveillance network was established on 163 
behalf of the European Fungal Infection Study Group, the 164 
International Society for Human and Animal Mycology 165 
Aspergillus terreus working group, and the European 166 
Confederation of Medical Mycology. 38 centres from 21 167 
countries participated. Each centre collected isolates and 168 
reported the number of A. terreus and fungal pathogens 169 
detected for 12 consecutive months (2014-2015). Patient 170 
characteristics’, epidemiological data, and antifungal 171 
treatment were documented through an online questionnaire 172 
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using www.clinicalsurveys.net online platform. Patients were 173 
classified according to the European Organisation for the 174 
Research and Treatment of Cancer/Mycoses Study Group 175 
consensus definitions [6] by the participating centres. Unless 176 
otherwise noted, the isolation of A. terreus from sputa of non-177 
neutropenic patients was categorized as colonisation. Isolates 178 
were sent to the Division of Hygiene and Medical Microbiology 179 
for molecular species identification [7,8] and susceptibility 180 
testing according to EUCAST (European Committee on 181 
Antimicrobial Susceptibility Testing) method [2]. A. terreus 182 
strains were identified to the cryptic species level by 183 
sequencing partial beta-tubulin and applying a validated in-184 
house database owned by Jos Houbraken, CBS Fungal 185 
Biodiversity Center, Utrecht, The Netherlands. An AMB 186 
epidemiological cut-off value of 4mg/L was set for A. terreus 187 
[2].   188 
This study was approved by the Ethics Commission of the 189 
Medical University of Innsbruck (UN4926). 190 
Results: 191 
461 cases were enrolled of which 91 were excluded because of 192 
insufficient patient documentation (n=45) or lack of fungal 193 
isolates (n=46) being available. Consequently, this survey 194 
comprises 370 eligible cases with an equal number of 195 
corresponding A. terreus isolates. Cases derived from Europe 196 
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(n=261), followed by Middle East (n=70), India (n=19), South 197 
America (n=10), and North America (n=10) (Figure 1). A. 198 
terreus sensu stricto (n=315), A. citrinoterreus (n=36), A. 199 
alabamensis (n=6), A. hortai (n=10), A. floccosus (n=1), and A. 200 
neoafricanus (n=1) were identified. One isolate (A. terreus 201 
1214) was most close to A. alabamensis and might represent a 202 
new species. Thus, cryptic species accounted for 14.9% 203 
(55/370) with A. citrinoterreus (36/55, 65.5%) being dominant.  204 
AMB MICs ranged from 0.125 to 32 mg/L for A. terreus sensu 205 
stricto; MICs for all cryptic species were consistently higher, 206 
ranging from 2 to 32 mg/L, see Table 1. According to the 207 
EUCAST cut-off values, 194 isolates (52.4%) were classified as 208 
non-wild types. A proportion of 6.3% (n=20) of the A. terreus 209 
sensu stricto isolates displayed lower MICs, ranging from 0.25 210 
– 0.5 mg/L. Isolates were predominantly acquired from Spain 211 
(n=85) and Austria (n=49), see Figure 1.  212 
Underlying diseases e described in Table 2. Species distribution 213 
did not differ per underlying disease and specimen 214 
investigated (Table 2). Diseases comprised IA (25.1%), allergic 215 
broncho-pulmonary aspergillosis (12.4%), chronic aspergillosis 216 
(11.4%), COPD exacerbation (5.5%), aspergilloma (3.7%), otitis 217 
externa (2.5%), and wound infections (0.7%). 25.1% and 27.3% 218 
of the patients suffered from proven and probable IA, 28.6% 219 
were colonized, 10.1% had onychomycosis, and 8.9% had 220 
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mycological documented diseases such as otitis externa, 221 
aspergilloma and others.   222 
Using a random effects model the pooled estimated 223 
proportion was 5.6% (95% CI 3.8 to 7.7) with I
2
 = 92% 224 
(p<0.0001) and the proportions ranged from 0.0% to 58.3%. 225 
These calculations were done with MedCalc 16.8.4. Four 226 
reference centres and one centre dealing with onychomycosis 227 
only were excluded from the analysis.  228 
A total of 68 patients received antifungal treatment at the 229 
time of fungal diagnosis, 12 were treated with AMB or 230 
liposomal - AMB. The remaining 56 received combinations of 231 
azoles and echinocandins and improved. Only one patient died 232 
due to the A. terreus infection. No information on outcome 233 
was available in 13 patients.  234 
 235 
Discussion: 236 
Infections due to A. terreus species complex were detected in 237 
21 countries and 38 centres with an overall prevalence of 5.2% 238 
among mold infections. High AMB MICs were frequently 239 
observed and crossed all cryptic species. Infections were 240 
reported from all over the world with three main specific 241 
findings. Firstly, Spain and Austria were the countries with the 242 
highest density of A. terreus isolates collected. Secondly, the 243 
number of A. terreus cases enrolled varied from centre to 244 
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centre, and displayed a broad range from zero to several cases 245 
per country. Thirdly, it seems that few susceptible AMB 246 
variants exist within A. terreus sensu stricto.  247 
Taking into account the differences on the environmental 248 
conditions, host related characteristics, and the use of 249 
antifungal agents, it is not possible to conclude on the 250 
particular biogeography of A. terreus species complex.  In 251 
addition, one has to be aware that data collected may depend 252 
on the quality of care, patient demographics, infection control 253 
practices, frequency of specimen collection, and laboratory 254 
methodology. Hence, further studies are needed to determine 255 
whether specific risk and/or environmental factors are 256 
associated with infections by A. terreus.   257 
Notable was the fact that Aspergillus section Terrei was most 258 
commonly isolated from patients suffering from chronic lung 259 
diseases (39.2%). No similar data have been reported [10] and 260 
it remains to be seen whether A. terreus reflects an emerging 261 
pathogen of this disease entity.    262 
A. terreus is a poor target for AMB and hence is reported as 263 
resistant [2]. The role of isolates with MICs <0.5 mg/L needs 264 
further evaluation. The pharmacodynamic target may be 265 
attained with the standard AMB dose for isolates with MICs 266 
≤0.25 mg/l [10] and infections were successfully treated with 267 
high dose liposomal-AMB [11]. 268 
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Cryptic species accounted for 14.8%, with A. citrinoterreus 269 
being the most prevalent. Although the clinical implications of 270 
sibling species of A. terreus are less well understood, our study 271 
confirms that these species are generally resistant to AMB and 272 
are causing a wide spectrum of invasive and non-invasive 273 
aspergillosis. Guinea et al. [12] observed A. citrinoterreus 274 
acting mainly as a co-pathogen with A. fumigatus. 275 
Our study has some limitations. We do not have a 276 
comprehensive worldwide A. terreus survey network and 277 
some countries are missing for a variety of reasons. Also, 278 
generally, the diagnosis of fungal infections is difficult to 279 
obtain and may often be based on detection of biomarkers 280 
rather than on isolation of the infecting organism. Hence, 281 
some cases may have been missed and chronic lung diseases 282 
were not specified in more detail. Further, we have no data 283 
available on co-infections which may complicate diseases. The 284 
centres included represent a convenience sample. However, 285 
this is the largest and geographically most diverse study on the 286 
contemporary epidemiology of A. terreus species complex 287 
infections worldwide.  288 
Our study shows that A. terreus sensu stricto is widely 289 
distributed in climatically divergent countries, and that cryptic 290 
species display high AMB MICs. A. terreus species complex was 291 
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most commonly isolated from patients suffering from chronic 292 
lung diseases (39.2%).   293 
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Table 1. Distribution of amphotericin B MICs against Aspergillus terreus species complex 
isolates collected during the study period and tested according to EUCAST methodology 
Species  
Amphotericin B MICs, mg/L  
0.125 0.25 0.5 1 2 4 8 16 32 
A. terreus sensu stricto 3 7 10 14 36 81 86 55 23 
A. citrinoterreus     3 13 8 7 5 
A. hortai     1 2 5 2  
A. alabamensis     2 3 1   
A. floccosus      1    
A. neoafricanus         1 
Potential new species       1   
 
Table 2. Species distribution of Aspergillus terreus species complex isolated from the various 
human specimens  
 
Species  
Specimens, total numbers   
Sputa Bronchoalveolar 
lavages and 
tracheal secretions 
Body- 
fluids 
Biopsies Swabs Others Total 
A. terreus sensu stricto 126 65 53 33 17 21 315 
A. citrinoterreus 14 7 3 5 3 4 36 
A. hortai 4 2   1 3 10 
A. alabamensis 3 2   1  6 
A. floccosus     1  1 
A. neoafricanus      1 1 
Potential new species    1   1 
Total  147 76 56 39 23 29 370 
* aspirates, wound secretions, nails 
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Fig. 1a - c. Overview of countries and Aspergillus terreus species complex isolated numbers 
collected during the study period:   
a) Aspergillus citrinoterreus 
b) Aspergillus terreus sensu stricto 
c) Aspergillus hortai 
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